CASS vs MRNA · P/E 21, rev $99.0M vs rev $145.0M
Cass Information Systems Inc (CASS) versus Moderna Inc (MRNA) — a side-by-side from cached financials, not a winner call.
Cass Information Systems Inc (CASS) is a specialty business services company listed on NASDAQ.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Latest reported CASS revenue for 2026-06-30 was $99.0M. Net income was $19.4M. CASS currently screens at market cap $627.2M and trailing P/E 20.8.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
CASS currently screens at market cap $627.2M and trailing P/E 20.8. MRNA currently screens at market cap $24.52B.
Not investment advice. Open the CASS and MRNA stock pages for the full models.
Not investment advice.